4-[(2'S,5'R,6'E)-2'-hydroxy-5',7'-dimethyl-4'-oxonona-6',8'-dienyl]piperidine-2,6-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-[(2'S,5'R,6'E)-2'-hydroxy-5',7'-dimethyl-4'-oxonona-6',8'-dienyl]piperidine-2,6-dione
• 英文别名: (-)-streptimidone；4-[(2S,5R,6E)-2-hydroxy-5,7-dimethyl-4-oxonona-6,8-dienyl]piperidine-2,6-dione
• 化学式: C₁₆H₂₃NO₄
• 分子量: 293.363
• InChiKey: ZRYKVDWGQVQRPG-MQBWTGGOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  21
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  83.5
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-(甲酰基甲基)戊二酰亚胺 、 (3R)-3,5-dimethylhepta-4,6-dien-2-one 在 lithium diisopropyl amide 作用下， 以 四氢呋喃 为溶剂， 反应 0.58h， 生成 4-[(2'S,5'R,6'E)-2'-hydroxy-5',7'-dimethyl-4'-oxonona-6',8'-dienyl]piperidine-2,6-dione 、 4-[(2'R,5'R,6'E)-2'-hydroxy-5',7'-dimethyl-4'-oxonona-6',8'-dienyl]piperidine-2,6-dione
  参考文献：
  名称：

  Streptimidone 的四种立体异构体的合成和抗真菌活性，一种来自 Streptomyces rimosus forma paromomycinus 的戊二酰亚胺抗生素

  摘要：

  链霉素 (1) 的四种立体异构体是一种来自 Streptomyces rimosus forma paromomycinus 的抗生素，由 (S)-3-hydroxy-2-methylpropanoate 合成。天然非对映异构体 1 显示出最强的抗菌活性。

  DOI：

  10.1002/1099-0690(200010)2000:20<3459::aid-ejoc3459>3.0.co;2-f

文献信息

• GLUTARIMIDE-CONTAINING POLYKETIDE ANALOGS AND METHODS THEREOF
  申请人：Shen Ben

  公开号：US20060211736A1

  公开（公告）日：2006-09-21

  The present invention provides library of glutarimide-containing polyketide analogs, such as analogs of migrastatin, iso-migrastatin, dorrigocin A and B, epi-dorrigocin, NK30424 A and B and lactimidomycin, methods of synthesizing and using these analogs and further methods of creating a combinatorial library of these compounds through chemical modifications.

  本发明提供了含有戊二酰亚胺的聚酮类类似物的文库，例如米格拉斯汀、异米格拉斯汀、多利戈辛A和B、表多利戈辛、NK30424 A和B以及乳酰亚胺类似物的类似物，以及合成和使用这些类似物的方法，以及通过化学修饰进一步创建这些化合物的组合文库的方法。
• RIBOSOME STRUCTURE AND PROTEIN SYNTHESIS INHIBITORS
  申请人：Steitz A. Thomas

  公开号：US20050036997A1

  公开（公告）日：2005-02-17

  The invention provides methods for producing high resolution crystals of ribosomes and ribosomal subunits as well as crystals produced by such methods. The invention also provides high resolution structures of ribosomal subunits either alone or in combination with protein synthesis inhibitors. The invention provides methods for identifying ribosome-related ligands and methods for designing ligands with specific ribosome-binding properties as well as ligands that may act as protein synthesis inhibitors. Thus, the methods and compositions of the invention may be used to produce ligands that are designed to specifically kill or inhibit the growth of any target organism.

  本发明提供了生产核糖体和核糖体亚基高分辨率晶体的方法，以及由这些方法产生的晶体。该发明还提供了核糖体亚基的高分辨率结构，无论是单独还是与蛋白质合成抑制剂结合。该发明提供了用于识别与核糖体相关的配体的方法，以及设计具有特定核糖体结合性质的配体的方法，以及可能起作用为蛋白质合成抑制剂的配体。因此，本发明的方法和组合物可用于生产专门设计用于杀灭或抑制任何目标生物生长的配体。
• Ribosome structure and protein synthesis inhibitors
  申请人：Steitz A. Thomas

  公开号：US20050272681A1

  公开（公告）日：2005-12-08

  The invention provides methods for producing high resolution crystals of ribosomes and ribosomal subunits as well as crystals produced by such methods. The invention also provides high resolution structures of ribosomal subunits either alone or in combination with protein synthesis inhibitors. The invention provides methods for identifying ribosome-related ligands and methods for designing ligands with specific ribosome-binding properties as well as ligands that may act as protein synthesis inhibitors. Thus, the methods and compositions of the invention may be used to produce ligands that are designed to specifically kill or inhibit the growth of any target organism.

  本发明提供了制备高分辨率核糖体和核糖体亚基晶体的方法，以及由这些方法产生的晶体。本发明还提供了核糖体亚基的高分辨率结构，无论是单独还是与蛋白质合成抑制剂结合。本发明提供了识别与核糖体相关的配体的方法，以及设计具有特定核糖体结合性质的配体的方法，以及可能作为蛋白质合成抑制剂的配体。因此，本发明的方法和组合物可用于生产旨在特异性杀死或抑制任何目标生物生长的配体。
• Migrastatin analogs in the treatment of cancer
  申请人：Danishefsky Samuel J.

  公开号：US20090124662A1

  公开（公告）日：2009-05-14

  In one aspect, the present invention provides a method for treating colon and/or ovarian cancer in a subject comprising administering to a subject in need thereof a compound of general formula (I): wherein R1-R6, R, -R, Q, Y1, Y2 and n are as defined herein, wherein the compound is present in an amount effective to inhibit colon and/or ovarian tumor metastasis.

  本发明在某一方面提供了一种治疗结肠和/或卵巢癌的方法，包括向需要该治疗的受试者施用一种通式(I)的化合物：其中R1-R6，R，-R，Q，Y1，Y2和n如本文所定义，在该化合物以有效量存在的情况下，以抑制结肠和/或卵巢肿瘤的转移。
• Migrastatin analogs and uses thereof
  申请人：Huang Xin-Yun

  公开号：US20070037783A1

  公开（公告）日：2007-02-15

  In one aspect, the present invention provides pharmaceutical compositions comprising a therapeutically effective amount of a compound of general formula (I), wherein R 1 —R 6 , R a—R C , Q, Y 1 , Y 2 and n are as defined herein, whereby the composition is formulated for administration to a subject at a dosage between about 0.1 mg/kg to about 50 mg/kg of body weight. In another aspect, the present invention provides a method for treating breast tumor metastasis in a subject comprising administering to a subject in need thereof a therapeutically effective amount of the inventive composition described directly above and a pharmaceutically acceptable carrier, adjuvant or vehicle.

  在一个方面，本发明提供了制剂，包括通式（I）中化合物的治疗有效量，其中R1-R6，Ra-RC，Q，Y1，Y2和n的定义如本文所述，该制剂被制成适用于给予受试者剂量在0.1毫克/千克到50毫克/千克的体重之间。在另一个方面，本发明提供了一种治疗乳腺肿瘤转移的方法，包括向需要治疗的受试者直接上述描述的创新制剂和药学上可接受的载体、佐剂或载体的治疗有效量的给药。